NEW YORK – Following a successful $3 million seed funding round earlier this month, University of California, San Diego spinout Micronoma is commercializing a blood-based diagnostic assay that identifies a patient’s organ microbiome signature to potentially detect early-stage cancers.  

Read the full story on GenoneWeb.